It is understood that the performance of the shopping festival will be presented in a variety of art forms such as dance, recitation, singing, fashion show, playing the chapter of "the more wonderful the night", with loud singing and beautiful dancing,

and provide a audio-visual feast. It is worth mentioning that Xiamen BOC staff will bring specially created and adapted songs, as well as a mouth drum with southern Fujian characteristics and different styles of dance performances, to celebrate the summer night with citizens and tourists.

Light and shadow reflect the unique charm of Zhongshan Road. The shopping festival will also combine the retro street lights and Nanyang style architecture of Zhongshan Road Pedestrian Street, and carefully set up light shows,

theme wish areas, creative sidewalk posters, etc. The flashing neon lights are set off against the buildings of Zhongshan Road, and the unique creative cultural and creative design activates the characteristics of the traditional old street "suitable for living,

enjoying and traveling", so that the walking street of Zhongshan Road radiates a different charm under the night.Shenghe Biology today from the IPO: core products are quite interesting commercialization accelerated growth potential considerable

From the perspective of the long-term fundamentals of the industry, the biopharmaceutical industry has always been a quality track to invest in.

With the extension of life expectancy and the increase of aging population, the population of cancer patients is expected to continue to grow, creating a huge demand for clinical treatment.

Compared with traditional therapies, tumor immunotherapy has the unique advantages of lasting efficacy and low side effects, and can reduce the economic burden of patients, and has a huge market opportunity.

In recent years, with the promotion of the market and the support of policies, the development of innovative drug industry has accelerated, many innovative drug companies have been listed in Hong Kong, and the innovative drug sector of Hong Kong stocks has continued to grow. On May 16,

the Hong Kong IPO market ushered in another innovative pharmaceutical company - Shenghe Biological Holdings Limited (hereinafter referred to as "Shenghe Biological", 2898.HK) in Hong Kong to open the IPO.

The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of biologics for the treatment of cancer and autoimmune diseases.

This offering, Shenghe biological intends to issue 34.1518 million shares, each issue price of HK $13.50, 200 shares per hand, is expected to land on the Hong Kong Stock Exchange on May 24.

Compared with other unprofitable biotechnology companies that have successfully landed in Hong Kong stocks, what are the unique features of Shenghe Biology in this offering?

Three technology platforms provide a powerful engine for development

Shenghe has strong internal research and development capability. As of the latest practicable date, the Company has a professional independent research and development team, of which 62.2% of the team members have a master's or doctoral degree in biology or medical related majors,

and have deep industry experience in the fields of cytokine mechanism of action, antibody drug discovery, protein engineering and antibody engineering, and biopharmaceutical project management.

With the support of our R&D team, we have rapidly built a fully integrated end-to-end independent R&D capability covering all key biologic drug development functions, including discovery,

antibody and protein engineering, process development, preclinical pharmacology, clinical development and Good Manufacturing practice (" GMP ") manufacturing, within six years. And has independent intellectual property rights of strengthening antibody cytokine platform (" AIC platform "),

ADCC enhanced antibody platform (" AEA platform ") and strengthening natural immune cell multi-antibody platform (" AIM platform ") three major technology platforms, forming a powerful engine to support the development of the company.

Among them, AIC platform has outstanding advantages in many aspects of antibody cytokine development, such as cytokine selection and optimization, antibody selection and engineering,

structural design and engineering, and customized production of cell lines, and has successfully solved the technical problems related to antibody cytokine development, such as antibody and cytokine selection and optimization, and final drug production.

The AEA platform is a bioengineered Chinese hamster ovary (" CHO ") cell line in which the FUT8 fragment has been knocked out, and by this modification, the CHO cell line will not be able to catalyze the transfer of fucose residues from its donor to its target,

thus unable to produce any fucose-carrying antibodies. In contrast to other platforms that aim to enhance ADCC by removing fucose from antibodies, the AEA platform is expected to produce antibodies with a 0% fucose content, rapidly, steadily and completely enhancing ADCC of antibodies and simplifying product quality control.